131I-Metaiodobenzylguanidine with Intensive Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma. A New Approaches to Neuroblastoma Therapy (NANT) Phase II Study
Author:
Funder
National Cancer Institute
Pediatric Cancer Research Foundation
Publisher
Elsevier BV
Subject
Transplantation,Hematology
Reference38 articles.
1. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study;Matthay;J Clin Oncol,2009
2. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of 1 year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry;Ladenstein;J Clin Oncol,1998
3. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial;Kreissman;Lancet Oncol,2013
4. Scintigraphic localization of pheochromocytoma;Sisson;N Engl J Med,1981
5. Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases;Shapiro;J Nucl Med,1985
Cited by 79 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Radioteragnosis en paragangliomas y feocromocitomas;Revista Española de Medicina Nuclear e Imagen Molecular;2024-07
2. Radio theranostics in paragangliomas and pheochromocytomas;Revista Española de Medicina Nuclear e Imagen Molecular (English Edition);2024-07
3. A narrative review of 35 years of meta-[131I]iodobenzylguanidine therapy in neuroblastoma;EJC Paediatric Oncology;2024-06
4. Navigating new horizons: Prospects of NET-targeted radiopharmaceuticals in precision medicine;Theranostics;2024
5. Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes;Cancers;2023-10-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3